US · RDY · DRUG MANUFACTURERS - SPECIALTY & GENERIC
Dr. Reddy's Laboratories Limited (RDY) intrinsic value and stock valuation
$14.89as of 2026-11-21 · Mkt cap 10.18B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Dr. Reddy's Laboratories Limited DCF and intrinsic value
InvestorsCraft values RDY with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from RDY’s statements →
Dr. Reddy's Laboratories Limited Graham Number
Graham Number: $738.91d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2012–2026, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Revolution Medicines, Inc. (RVMD) $161.20
- Viatris Inc. (VTRS) $19.63
- Neurocrine Biosciences, Inc. (NBIX) $150.57
- Solventum Corporation (SOLV) $84.50
- Exelixis, Inc. (EXEL) $64.63
- Elanco Animal Health Incorporated (ELAN) $25.74
- Revvity, Inc. (RVTY) $145.22
- BioMarin Pharmaceutical Inc. (BMRN) $60.41
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $353.5B | $325.5B | $279.2B | $245.9B | $214.4B |
| Operating income | $48.9B | $71.8B | $67.7B | $57.1B | $29.5B |
| Net income | $45.1B | $56.5B | $55.7B | $45.1B | $23.6B |
| EPSd | $54.1M | $67.8M | $66.8M | $54.2M | $28.3M |
| Operating cash flow | $56.6B | $46.4B | $45.4B | $58.9B | $28.1B |
| Capital expenditure | -$-24.54B | -$-34.4B | -$-27.44B | -$-18.87B | -$-19.05B |
| Free cash flow | $32.1B | $12B | $18B | $40B | $9.06B |
| Total assets | $567.9B | $493B | $387.5B | $321.9B | $292.8B |
| Total debt | $75.8B | $46.8B | $20B | $13.5B | $33.8B |
| Net debt | $60.7B | $32.1B | $12.9B | $7.69B | $19B |
| Total equity | $372.9B | $337.2B | $280.6B | $231B | $190.5B |
| Cash and short-term investments | $86.1B | $57.9B | $81.5B | $61.8B | $44.4B |
Income statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Revenue | $353.5B | $325.5B | $279.2B | $245.9B | $214.4B |
| Cost of revenue | $167B | $135.1B | $115.6B | $106.5B | $100.6B |
| Gross profit | $186.5B | $190.4B | $163.6B | $139.3B | $113.8B |
| Research and development expenses | $25.3B | $27.4B | $22.9B | $19.4B | $17.5B |
| Selling, general and administrative expenses | $112.3B | $93.9B | $77.2B | $68B | $62.1B |
| Other expenses | $0.00 | -$-2.67B | -$-4.2B | -$-5.21B | $4.8B |
| Operating expenses | $137.7B | $118.6B | $95.9B | $82.2B | $84.4B |
| Cost and expenses | $304.6B | $253.7B | $211.4B | $188.7B | $184.9B |
| Interest income | $8.28B | $2.68B | $2.28B | $1.18B | $965M |
| Interest expense | $3.93B | $2.83B | $1.71B | $1.43B | $958M |
| Depreciation and amortization | $21.7B | $17.1B | $14.8B | $12.6B | $11.8B |
| Ebitda | $83.3B | $96.7B | $88.4B | $74.4B | $45.1B |
| Operating income | $48.9B | $71.8B | $67.7B | $57.1B | $29.5B |
| Total other income/expenses, net | $8.81B | $4.94B | $4.14B | $3.22B | $2.82B |
| Income before tax | $57.7B | $76.8B | $71.9B | $60.4B | $32.3B |
| Income tax expense | $13B | $19.5B | $16.2B | $15.3B | $8.73B |
| Net income | $45.1B | $56.5B | $55.7B | $45.1B | $23.6B |
| Weighted average shares outstanding | $832.4M | $833.3M | $833.5M | $830.2M | $829.4M |
| Weighted average diluted shares outstanding | $833.3M | $834.3M | $833.5M | $831.9M | $831.7M |
Balance sheet
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $86.1B | $57.9B | $81.5B | $61.8B | $44.4B |
| Net receivables | $99.2B | $109.8B | $95.3B | $83.2B | $80.3B |
| Inventory | $75B | $71.1B | $63.6B | $48.7B | $50.9B |
| Total current assets | $296B | $250.1B | $248B | $204.3B | $181.9B |
| Property, plant and equipment, net | $113.6B | $97.8B | $76.9B | $66.5B | $62.2B |
| Goodwill and intangible assets | $115.6B | $108.6B | $41.2B | $35.1B | $31.7B |
| Long-term investments | $16B | $15.2B | $5.26B | $5.36B | $7.99B |
| Total non-current assets | $271.9B | $242.9B | $139.5B | $117.6B | $111B |
| Total assets | $567.9B | $493B | $387.5B | $321.9B | $292.8B |
| Accounts payable | $32.7B | $20.1B | $21.5B | $17.9B | $16B |
| Short-term debt | $63.8B | $38.9B | $14B | $12.2B | $28.1B |
| Deferred revenue | $0.00 | $1.98B | $1.44B | $1.98B | $2.58B |
| Total current liabilities | $164.2B | $130.4B | $96B | $85.8B | $94B |
| Long-term debt | $12B | $7.86B | $5.99B | $1.28B | $5.75B |
| Deferred revenue, non-current | $0.00 | $1.16B | $1.19B | $1.56B | $1.6B |
| Total non-current liabilities | $30.7B | $25.4B | $10.9B | $5.02B | $8.29B |
| Capital lease obligations | $0.00 | $4.92B | $3.5B | $2.28B | $2.96B |
| Total liabilities | $195B | $155.8B | $107B | $90.9B | $102.3B |
| Common stock | $818.5M | $834M | $834M | $833M | $832M |
| Retained earnings | $345B | $315.8B | $265.3B | $215.6B | $175.7B |
| Accumulated other comprehensive income (loss) | $10.5B | $3.98B | $653M | $886M | $755M |
| Total equity | $372.9B | $337.2B | $280.6B | $231B | $190.5B |
| Total investments | $87.1B | $58.5B | $79.6B | $61.4B | $37.5B |
| Total debt | $75.8B | $46.8B | $20B | $13.5B | $33.8B |
| Net debt | $60.7B | $32.1B | $12.9B | $7.69B | $19B |
Cash flow statement
| 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| Net income | $45.1B | $57.2B | $55.7B | $45.1B | $23.6B |
| Depreciation and amortization | $21.7B | $17.1B | $14.8B | $12.6B | $11.8B |
| Stock-based compensation | $0.00 | $424M | $407M | $397M | $592M |
| Change in working capital | -$-12.24B | -$-29.99B | -$-20.18B | -$-7.86B | -$-13.91B |
| Accounts receivable | -$-7.07B | -$-10.28B | -$-8.05B | -$-5.75B | -$-17.01B |
| Inventory | -$-9.05B | -$-12.75B | -$-18.45B | -$-2.65B | -$-5.33B |
| Accounts payable | $2.94B | $0.00 | $0.00 | $0.00 | $17B |
| Net cash provided by operating activities | $56.6B | $46.4B | $45.4B | $58.9B | $28.1B |
| Investments in property, plant and equipment | -$-40.43B | -$-27.5B | -$-16.4B | -$-11.32B | -$-19.05B |
| Acquisitions, net | -$-2.99B | -$-53.41B | -$-12M | $0.00 | -$-326M |
| Net cash used for investing activities | -$-70.53B | -$-58.08B | -$-40.28B | -$-41.37B | -$-26.39B |
| Common stock issued | $417.7M | $193M | $805M | $368M | $334M |
| Common stock repurchased | $0.00 | -$-1.39B | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-7.01B | -$-6.66B | -$-6.65B | -$-4.98B | -$-4.15B |
| Net cash used for financing activities | $13.4B | $18.9B | -$-3.76B | -$-26.86B | -$-2.42B |
| Net change in cash | -$-875.84M | $7.49B | $1.33B | -$-9.07B | $32M |
| Cash at end of period | $15.1B | $14.6B | $7.11B | $5.78B | $14.9B |
| Operating cash flow | $56.6B | $46.4B | $45.4B | $58.9B | $28.1B |
| Capital expenditure | -$-24.54B | -$-34.4B | -$-27.44B | -$-18.87B | -$-19.05B |
| Free cash flow | $32.1B | $12B | $18B | $40B | $9.06B |
Line items
Line items
Line items
About Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.
- CEO
- Erez Israeli
- Employees
- 27.53K
- Beta
- 0.25
Explore
Frequently asked questions
What is the intrinsic value of Dr. Reddy's Laboratories Limited (RDY)?
Dr. Reddy's Laboratories Limited (RDY) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is RDY undervalued?
RDY trades at a price of $14.89 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.